Piana Lucien, Leandri François-Xavier, Le Retraite Laurence, Heid Patrice, Tamalet Catherine, Sancho-Garnier Hélène
Association pour la recherche et le dépistage des cancers du sein, du col de l'utérus et des cancers colorectaux (Arcades), parc Mure, bâtiment A, 16, boulevard des Aciéries, 13010 Marseille, France.
Bull Cancer. 2011 Jul;98(7):723-31. doi: 10.1684/bdc.2011.1388.
The non-participation to cervical screening is the major determinant in the risk of mortality due to cervical cancer. In France, around 40% of women do not participate to regular screening. The cultural or economic barriers for performing screening by Pap test are numerous; one of the most frequent is the refusal of gynaecological examination. A persistent HPV(HR) infection is a necessary factor for developing cervical cancer. The HPV(HR) testing has a high sensibility to detect high grade cervical intra-epithelial neoplasia (CIN 2-3) and a satisfactory specificity after 30-35 years old. The principal objective of this study was to compare the participation rates in women 35-69 years old who did not perform a Pap test after a first individual invitation, either when an HPV(HR) auto-test was offered to be performed at home or a second invitation to Pap test was sent. We also evaluated the quality of the two tests, the positive results obtained by age groups and the following histological type of lesions diagnosed in the women with positive results. The study included 9,334 women, 35-69 years old, who did not realized a Pap-test during the 2 previous years and who did not respond at a first individual invitation. These non-responders were randomized into two groups: one group (n=4,934) received a second individual invitation and the other (n=4,400) an offer of receiving and performing an HPV auto-test at home. In women 35-69 years the participation to the second invitation to Pap test was significantly lower (7.2%) than the participation to auto-test (26.4%) with P<0.001. The quality of the two tests was satisfactory; the auto-test was not altered by the postage to laboratory (non interpretable rate=1.4% [CI at 95%=0.65%; 2.15%]. From the 311 Pap tests done, 5.5% (17) were classified "abnormal" (nine ASCUS, one high grade and seven low grades). The follow up of 13 women out of 17 confirmed the diagnosis for 1 case of CIN2 and 2 cases of CIN3, 4 women are lost of follow up after 6 months. From the 939 HPV(HR) tests done, 6.2% (58) were positive. Such positivity rate was not influenced by age. Out of the 58 positive HPV(HR) cases, 27 only were of the 16 genotype (46.5% [CI 95%=33.7%; 59.3%]). This law rate is a consequence of an inversion of the ratio HPV 16 versus other types in women 60 years old and over. In this group, the follow-up of 36 women diagnosed five cases of CIN1, one of CIN2 and four of CIN3; 22 patients are lost of follow up at 6 months. Globally, in the studied population, an individual recall for pap test allowed to diagnose and treat 3 high grade lesions (7‰) and the dispatching of an auto test allowed the diagnosis and treatment of five high grade lesions (1,4‰), this difference is significant (P=0.02; OR=0.25 [0.05; 0.97]). The HPV(HR) auto-test seems to be better accepted than the Pap test in the 35-69 years old women previously non-responders to individual invitation, and the quality of the test is satisfactory. Such a test can be proposed to the 35-69 years old non-participant to Pap test to increase the coverage for cervical screening, if the rates of diagnostic examinations performed in case of an HPV(HR) positive is sufficiently high.
未参加宫颈癌筛查是宫颈癌死亡风险的主要决定因素。在法国,约40%的女性未参加定期筛查。进行巴氏试验筛查存在诸多文化或经济障碍;最常见的障碍之一是拒绝妇科检查。持续性高危型人乳头瘤病毒(HPV)感染是宫颈癌发生的必要因素。高危型HPV检测对检测高级别宫颈上皮内瘤变(CIN 2 - 3)具有高敏感性,在30 - 35岁之后特异性良好。本研究的主要目的是比较35 - 69岁女性在首次个人邀请后未进行巴氏试验的情况下,提供在家自行进行高危型HPV检测或再次邀请进行巴氏试验时的参与率。我们还评估了两种检测的质量、按年龄组获得的阳性结果以及阳性结果女性中确诊的病变组织学类型。该研究纳入了9334名35 - 69岁的女性,她们在过去两年未进行巴氏试验且对首次个人邀请未回应。这些未回应者被随机分为两组:一组(n = 4934)收到再次个人邀请,另一组(n = 4400)收到在家自行进行高危型HPV检测服务。在35 - 69岁女性中,对再次巴氏试验邀请的参与率(7.2%)显著低于自行检测的参与率(26.4%),P < 0.001。两种检测质量均令人满意;自行检测不受邮寄至实验室的影响(无法解读率 = 1.4% [95%置信区间 = 0.65%;2.15%])。在311次巴氏试验中,5.5%(17例)被分类为“异常”(9例非典型鳞状细胞不能明确意义、1例高级别和7例低级别)。17例中的13例女性进行随访,确诊1例CIN2和2例CIN3,4例女性在6个月后失访。在939次高危型HPV检测中,6.2%(58例)为阳性。该阳性率不受年龄影响。在58例高危型HPV阳性病例中,仅27例为16型(46.5% [95%置信区间 = 33.7%;59.3%])。该低比例是60岁及以上女性中HPV 16型与其他类型比例倒置的结果。在该组中,36例女性进行随访,确诊5例CIN1、1例CIN2和4例CIN3;22例患者在6个月后失访。总体而言,在研究人群中,个人召回进行巴氏试验可诊断和治疗3例高级别病变(7‰),发放自行检测可诊断和治疗5例高级别病变(1.4‰),差异具有统计学意义(P = 0.02;OR = 0.25 [0.05;0.97])。对于之前对个人邀请未回应的35 - 69岁女性,高危型HPV自行检测似乎比巴氏试验更易被接受,且检测质量令人满意。如果高危型HPV阳性时进行诊断性检查的比例足够高,可向35 - 69岁未参加巴氏试验的女性提供此类检测,以提高宫颈癌筛查覆盖率。